TY - JOUR
T1 - Everolimus (RAD001)
T2 - An mTOR inhibitor for the treatment of metastatic renal cell carcinoma
AU - Oudard, Stéphane
AU - Mediodini, Jacques
AU - Aylllon, Jorge
AU - Barrascourt, Eduardo
AU - Elaidi, Reza Thierry
AU - Balcaceres, José
AU - Scotte, Florian
N1 - Funding Information:
Writing assistance was utilized in the production of this manuscript. Funding for medical writing support was provided by Novartis.
PY - 2009/8/31
Y1 - 2009/8/31
N2 - The recent introduction of drugs that inhibit angiogenesis or the mTOR has provided new options for the treatment of metastatic renal cell carcinoma, a disease which often has a poor prognosis. Chemotherapy and cytokine therapy are largely ineffective. The 5-year survival rate is under 10%. Everolimus, an immunosuppressive drug widely used for the prevention of allograft rejection and an mTOR inhibitor, is one of the latest drugs undergoing clinical trials in metastatic renal cell carcinoma. It has been tested in patients with progressive disease after therapy with tyrosine kinase receptor inhibitors (sunitinib, sorafenib or both), which interfere with signaling pathways, such as the VEGF pathway. Clinical efficacy results (progression-free survival) for everolimus are promising and the safety profile is good.
AB - The recent introduction of drugs that inhibit angiogenesis or the mTOR has provided new options for the treatment of metastatic renal cell carcinoma, a disease which often has a poor prognosis. Chemotherapy and cytokine therapy are largely ineffective. The 5-year survival rate is under 10%. Everolimus, an immunosuppressive drug widely used for the prevention of allograft rejection and an mTOR inhibitor, is one of the latest drugs undergoing clinical trials in metastatic renal cell carcinoma. It has been tested in patients with progressive disease after therapy with tyrosine kinase receptor inhibitors (sunitinib, sorafenib or both), which interfere with signaling pathways, such as the VEGF pathway. Clinical efficacy results (progression-free survival) for everolimus are promising and the safety profile is good.
KW - Everolimus
KW - MTOR inhibitor
KW - Metastatic renal cell carcinoma
KW - Progression-free survival
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=68849123146&partnerID=8YFLogxK
U2 - 10.1586/ERA.09.27
DO - 10.1586/ERA.09.27
M3 - Article
C2 - 19496707
AN - SCOPUS:68849123146
SN - 1473-7140
VL - 9
SP - 705
EP - 717
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 6
ER -